Compare Abbott Laboratories (ABT) vs Coinbase Global, Inc. (COIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Coinbase Global, Inc. — how do they compare? Abbott Laboratories trades at $95.59 (market cap $166.94B), while Coinbase Global, Inc. trades at $160.15 (market cap $43.08B). The key difference: Abbott Laboratories is far larger — about 3.9× Coinbase Global, Inc.'s market cap, and Abbott Laboratories pays a 2.63% dividend while Coinbase Global, Inc. pays none. Which is the better fit depends on your goals.
| ABT | COIN | |
|---|---|---|
Market Cap | $166.94B | $43.08B |
Sector | Health | Technology |
52-Week High | $136.62 | $419.78 |
52-Week Low | $82.57 | $141.09 |
Enterprise Value | $193.69B | $40.36B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
COIN trades at $163.51, down 1.19% over 24 hours, with a bearish technical signal and mixed earnings history. The company reported $7.18B revenue in 2025 with a net income margin of 12.2%, though recent quarters showed misses against EPS expectations. Analyst consensus remains bullish with a $233.08 price target, but cash flow trends indicate potential pressure as operating cash flow declined to $2.4B in 2025 from $2.6B in 2024.
The outlook for COIN hinges on execution amid volatile crypto markets, with 55% of analysts rating it a buy. Key risks include regulatory uncertainty and competitive threats, while institutional adoption growth offers upside. Investors should weigh high valuation multiples against earnings volatility and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →
